Key Takeaways
- Patient Assistance Programs (PAPs) and manufacturer copay assistance programs provide free or reduced-cost drugs to eligible patients — and can dramatically reduce plan costs for specialty drugs.
- Manufacturer copay cards reduce member out-of-pocket costs but may not reduce plan costs — and can actually increase them by allowing members to bypass cost-sharing designed to encourage lower-cost alternatives.
- Copay accumulator and maximizer programs are plan design tools that capture the value of manufacturer assistance for the plan rather than the member.
- PAPs are primarily for uninsured or underinsured patients — but some programs cover insured patients when the drug is not covered or cost-sharing is prohibitive.
- Navigating manufacturer assistance programs requires dedicated resources — either internal staff or a specialty pharmacy with a patient assistance team.
Types of Manufacturer Drug Assistance
Pharmaceutical manufacturers offer several types of financial assistance programs for patients who cannot afford their drugs. These programs exist for a mix of altruistic and commercial reasons — manufacturers want patients on their drugs, and assistance programs reduce the barrier to access.
| Program Type | Who It Serves | How It Works |
|---|---|---|
| Patient Assistance Programs (PAPs) | Uninsured or underinsured patients | Free drug provided directly by manufacturer based on income eligibility |
| Manufacturer copay cards | Commercially insured patients | Manufacturer pays member's copay or coinsurance up to an annual maximum |
| Free trial programs | New patients starting therapy | Free supply for first 30–90 days to encourage initiation |
| Foundation assistance | Patients with financial hardship | Independent foundations funded by manufacturers provide grants for drug costs |
| Bridge programs | Patients awaiting insurance approval | Free drug while prior authorization is pending |
The Copay Card Problem
Manufacturer copay cards are the most widely used form of drug assistance for commercially insured patients. They work by having the manufacturer pay the member's cost-sharing — copay or coinsurance — at the pharmacy. The member pays nothing out of pocket. The plan pays its full share of the drug cost.
The problem: copay cards undermine plan design. When a plan places a high-cost brand drug on a non-preferred tier with high cost-sharing to encourage use of a lower-cost alternative, a copay card eliminates that cost-sharing signal. The member has no financial incentive to choose the lower-cost drug. The plan pays the full cost of the high-cost drug — and the manufacturer has effectively neutralized the plan's cost-containment strategy.
Manufacturer copay cards are estimated to cost employer health plans $13 to $20 billion annually by undermining formulary management and cost-sharing design. They are not a benefit to the plan — they are a manufacturer marketing tool that shifts cost to the plan while appearing to help the member.
Copay Accumulators and Maximizers
Copay accumulator and maximizer programs are plan design tools that recapture the value of manufacturer assistance for the plan rather than allowing it to undermine cost-sharing.
- Copay accumulator programs: Manufacturer copay card payments do not count toward the member's deductible or out-of-pocket maximum. Once the copay card is exhausted, the member faces full cost-sharing — creating a financial incentive to switch to a lower-cost alternative.
- Copay maximizer programs: The plan adjusts the member's cost-sharing to exactly match the manufacturer's annual copay card maximum — ensuring the manufacturer pays the maximum amount while the member pays nothing. The plan's net cost is reduced by the manufacturer's contribution.
- Specialty drug carve-out with accumulator: Specialty drugs are carved out to a specialty pharmacy that applies accumulator logic — manufacturer assistance does not count toward accumulators.
Copay maximizer programs can generate $5,000 to $20,000 in manufacturer contributions per member per year for high-cost specialty drugs. For a plan with 20 members on specialty biologics, this can represent $100,000 to $400,000 in annual plan savings. Ask your PBM whether they offer a maximizer program.
Patient Assistance Programs for Insured Members
Traditional PAPs are designed for uninsured patients, but some manufacturers offer assistance to insured patients when the drug is not covered by insurance or when cost-sharing is prohibitive. Navigating these programs requires knowledge of each manufacturer's eligibility criteria and application process.
- Some PAPs cover insured patients who have exhausted their copay card benefit or who face cost-sharing above a defined threshold.
- Independent foundations — funded by manufacturers but operated independently — often have broader eligibility criteria than manufacturer-direct PAPs.
- Specialty pharmacies with dedicated patient assistance teams can identify and apply for PAP eligibility on behalf of members, reducing the administrative burden on the employer and member.
- PAP enrollment can take 2 to 6 weeks — bridge programs provide free drug while the application is processed.
Building a Drug Assistance Navigation Program
Maximizing the value of manufacturer assistance programs requires a systematic approach. Most employers do not have the internal resources to manage this — a specialty pharmacy with a patient assistance team is the most practical solution.
- 1Identify members on high-cost specialty drugs who may be eligible for manufacturer assistance.
- 2Enroll eligible members in copay card programs — but pair with a maximizer program to capture the value for the plan.
- 3Implement a copay accumulator for specialty drugs to prevent copay cards from undermining formulary management.
- 4Partner with a specialty pharmacy that has a dedicated patient assistance team to manage PAP applications and foundation grants.
- 5Track manufacturer assistance received per member and per drug — this data is essential for measuring program ROI.
Your Action Steps
- 1Identify members on specialty drugs with manufacturer copay card programs — estimate the annual copay card value available.
- 2Ask your PBM whether your current plan design includes a copay accumulator or maximizer program for specialty drugs.
- 3If not, evaluate implementing a copay maximizer for your top 5 specialty drugs by spend.
- 4Review your specialty pharmacy contract — does the pharmacy have a patient assistance team that actively enrolls eligible members in PAPs and foundation programs?
- 5Calculate the potential plan savings from a copay maximizer program on your current specialty drug population.
- 6Ensure your SPD and plan document are updated to reflect any copay accumulator or maximizer provisions — members must be notified that manufacturer assistance does not count toward accumulators.
Knowledge Check
5 questions · passing score 4/5
Test your understanding of this module. You need 4 out of 5 correct to pass. You can retake the quiz as many times as you like.